Literature DB >> 19005279

Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy.

Emma Hammond1, Elizabeth McKinnon, Simon Mallal, David Nolan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19005279     DOI： 10.1097/QAD.0b013e328319807f

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  12 in total

1.  Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase.

Authors:  Paul D Baum; Paul M Sullam; Cheryl A Stoddart; Joseph M McCune
Journal:  AIDS       Date:  2011-11-28       Impact factor: 4.177

2.  Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy.

Authors:  Michael S Boger; Aihua Bian; Ayumi Shintani; Ginger L Milne; Jason D Morrow; Husamettin Erdem; Valerie Mitchell; David W Haas; Todd Hulgan
Journal:  Antivir Ther       Date:  2011-12-14

3.  Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens.

Authors:  Corrilynn O Hileman; David A Wohl; Daniel J Tisch; Sara M Debanne; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-26       Impact factor: 2.205

4.  Switching antiretroviral therapy to minimize metabolic complications.

Authors:  Jordan E Lake; Judith S Currier
Journal:  HIV Ther       Date:  2010-11

5.  Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.

Authors:  Kunchok Dorjee; Tsering Choden; Sanjiv M Baxi; Craig Steinmaus; Arthur L Reingold
Journal:  Int J Antimicrob Agents       Date:  2018-07-21       Impact factor: 5.283

6.  Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women.

Authors:  Iain J MacLeod; Christopher F Rowley; Shahin Lockman; Anthony Ogwu; Sikhulile Moyo; Erik van Widenfelt; Mompati Mmalane; Joseph Makhema; M Essex; Roger L Shapiro
Journal:  J Int AIDS Soc       Date:  2012-07-10       Impact factor: 5.396

7.  Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.

Authors:  Sergio Padilla; Mar Masiá; Natalia García; Inmaculada Jarrin; Consuelo Tormo; Félix Gutiérrez
Journal:  BMC Infect Dis       Date:  2011-02-04       Impact factor: 3.090

8.  Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Jesper Melchjorsen; Christian A Frederiksen; Ulla S Nielsen; Bente L Langdahl; Lars Østergaard; Alex L Laursen
Journal:  BMC Infect Dis       Date:  2011-10-04       Impact factor: 3.090

9.  The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients.

Authors:  Gerard Aragonès; Pedro Pardo-Reche; Laura Fernández-Sender; Anna Rull; Raúl Beltrán-Debón; Esther Rodríguez-Gallego; Jordi Camps; Jorge Joven; Carlos Alonso-Villaverde
Journal:  Mediators Inflamm       Date:  2012-05-07       Impact factor: 4.711

10.  Relaxation effect of abacavir on rat basilar arteries.

Authors:  Rachel Wai Sum Li; Cui Yang; Shun Wan Chan; Maggie Pui Man Hoi; Simon Ming Yuen Lee; Yiu Wa Kwan; George Pak Heng Leung
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.